Prediction of Cardiovascular Events in Vulnerable Patients Following Acute Coronary Syndrome

Mayo Clinic101 enrolled

Overview

The purpose of this study is to determine if testing patients for endothelial dysfunction will help identify which patients are more likely at risk to have another heart attack in the future. Study participants will undergo mental stress testing while at the same time being connected to a device that measures endothelial function via the Endopat device. These same participants will also undergo a sleep study via the Watchpat device.

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

101

Conditions

Acute Coronary Syndrome

Interventions

EndoPAT testing (non invasive device)OTHER

Using the EndoPAT device, we will assess endothelial function.

WatchPAT testing (non-invasive device)OTHER

Using the WATCHPAT device we will assess sleep apnea.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients undergoing revascularization by percutaneous intervention (PCI) for Acute Coronary Syndrome (ACS) at Mayo (STEMI and NonSTEMI patients) 2. Age greater than 18 Exclusion Criteria: 1. Patients likely not to complete the study due to co-morbid conditions (end stage renal disease; liver failure; malignancies) 2. Inability to sign a consent form or availability for follow up 3. Patients unable to tolerate the blood pressure cuff inflation on both arms 4. patients with tremors 5. sustained non-sinus cardiac arrhythmias 6. acrylic finger nails 7. permanent pacemaker 8. color blindness 9. use of alpha blockers and short acting nitrates \< 3 hours before study 10. Federal Medical Center inmates

Locations (1)

Mayo Clinic

Rochester, Minnesota, United States

Outcomes

Primary Outcomes

Unstable Angina, Myocardial Infarction, Repeat Revascularization, Cardiac Death, Stroke

Time frame: Will determine with statistical analysis after all patients have had 2 year follow-up

Secondary Outcomes

Quality of Life

Quality of Life as assessed by SF12

Time frame: 6 months post revascularization.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.